Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Oasmia Pharmaceutical

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Docetaxel

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: SAKK

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement June 08, 2020

            Details:

            SAKK is the legal sponsor of the project and responsible to conduct the phase 1B trial. Oasmia’s main role in the project is to supply its formulation of docetaxel and carry the cost of the trial, which are deemed not material to Oasmia.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Docetaxel

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 14, 2020

            Details:

            Data collected from the Company’s development program of docecal, a solvent-free nanoparticle micellar formulation of docetaxel have been accepted for a poster presentation at the American Society of Clinical Oncology (ASCO) 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Docetaxel

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 13, 2020

            Details:

            As a result of the review, Oasmia decided to continue the development of Oasmia’s existing pipeline of XR17-based products, including Docecal (docetaxel) in breast and prostate cancers and its combination cancer therapy XR19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Paclitaxel,Carboplatin

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Elevar Therapeutics

            Deal Size: $698.0 million Upfront Cash: $20.0 million

            Deal Type: Partnership April 21, 2020

            Details:

            The global strategic partnership deal is signed regarding the commercialization of Oasmia’s anticancer product Apealea®.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Paclitaxel

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Elevar Therapeutics

            Deal Size: Undisclosed Upfront Cash: $20.0 million

            Deal Type: Partnership March 26, 2020

            Details:

            The partnership between Oasmia and Elevar grants Elevar the exclusive right to commercialize Apealea®, in all global territories, except countries in which Oasmia and its partners are already present.